Someone asked me for a list of 'proteomics companies' recently. FWIW, here's someone else's effort -
SAN JOSE, Calif.--(BUSINESS WIRE)--Sept. 12, 2000--Proteomics is an important, but evolutionary, stage of drug development which studies the entire differential output of proteins by cells under disease, drug or environmental challenge.
Already a multi-million dollar business and poised to increase several-fold over the next 5 years, proteomics is riding the wave of the human genome ``completion'' and building on the prior success of genomics to become the ``next big thing'' in drug discovery.
According to the latest Frost & Sullivan (www.frost.com) research entitled ``World Proteomics Markets,'' genomics is helping to drive growth of the proteomics markets, which was estimated at approximately $700 million in 1999, to approximately $5.8 billion in 2005.
Genomics involves the discovery of genes and their functions. Proteomics offers perhaps a more realistic hope, than does genomics, of achieving the kind of growth sought by biopharmaceutical companies because it is closer to the actual disease process. With genomics discovering thousands of genes, techniques such as proteomics will be required to help sort out function and select relevant drug and diagnostic targets.
Originally, proteomics meant the isolation and identification of proteins from normal versus perturbed cells. Today, proteomics encompasses aspects of functional genomics (linking protein expression with gene expression), structural proteomics (determining large numbers of protein 3-D structures by spectroscopic or computational techniques), and protein-protein interaction and biochemical pathway studies.
``The main difference between the old and new paradigms is in the high-throughput, parallel thinking that is now applied to the science,'' stated Dr. Stefan Unger, Ph.D, Director of Drug Discovery Technologies for Frost & Sullivan. ``There are no clear winners in these early stages of market development for proteomics, which means there is a wealth of opportunity.''
The four segments of the proteomics market, as analyzed by Frost & Sullivan's research are: Instruments, ``wet'' technologies & Supplies, Laboratory Services, and Bioinformatics. The myriad of potential medical and diagnostic applications of proteomics are not covered in this research.
``With over 40 commercial funding activities of various types (VC, IPO, mergers, etc.), this is a very rapid pace for a discipline that was unnamed just six years ago,'' says Dr. Unger.
Organizations & Companies involved in the World Proteomics Markets as identified by this Frost & Sullivan research project include: Agilent Technologies Inc. (Hewlett-Packard), Alcon, AlphaGene Inc., Amersham Pharmacia Biotech AB, Amgen Inc., Astex Technology Ltd., Atheris Laboratories SA, Aurora Biosciences Corp., Automated Cell Technologies Inc., AxCell Biosciences Corp. (Cytogen), Bay Bioanalytical Laboratory Inc., Bayer Corp, Beckman Coulter Inc., Biacore AB, Bio-Information Technologies Ltd., Biomax Informatics GmbH, BioMolecular Instruments (Thermo Instrument Systems Inc.), BioNexus Genomics Inc. (Ashni Naturaceuticals), Bio-Rad Laboratories Inc., BioTools Inc., Biovation Ltd., BioVision GmbH & Co. KG, BioWhittaker Molecular Applications Inc. (FMC Bioproducts), Bohdan Automation, Borealis Biosciences Inc., Brax Group Ltd., Bruker Daltonics Inc., C.B.S. Scientific Inc., Cambridge Anta, Cambridge Antibody Technology PLC, Cambridge Drug Discovery Ltd., Celera Genomics Corp., Chalon Biotech Inc., Ciphergen BioSystems Inc., CombiMatrix Corp. (sub of Acacia), Commonwealth Biotechnologies Inc., Compugen Ltd., Comstock Inc., Curagen Corp., Curtis & Tompkins Ltd., diaDexus, DoubleTwist Inc. (Pangea), Dyax Corp., Emerald Biostructure Inc., ESA Inc., Europroteome SA, Fisher Scientific, Gene Data AG, Gene Machines, GeneFormatics Inc., Genespan Corp., Genetics Institute Inc., GeneTrace Inc., Geneva Bioinformatics SA (GeneBio), Genome Pharmaceutical Corp. Biotech AG, Genomic Solutions, Inc., Genset SA, Glaxo Wellcome, Glyko Inc., Gradipore Ltd., GSG Analytical Instruments Ltd., HTS Biosystems Inc., Hybrigenics SA, ICN Biomedicals Inc., Incyte Genomics Ltd., InforMax Inc., Inpharmatica Ltd., Intrinsic Bioprobes Inc., IonSpec Corp., Jerini Bio Tools GmbH, Jule Biotechnologies Inc., Kendrick Labs Inc., Kore Technology Ltd., Kratos Analytical Inc. (Shimadzu), Lab Connections Inc., Large Scale Biology Corp./ Large Scale Proteomics Corp., Life Technologies Inc., LION Bioscience AG, Lynx Therapeutics Inc., Mass Consortium Corp., Matrix Science Ltd., MDS Protana AS, MDS Proteomics Inc., MDS Sciex, Media Cybernetics LP, MediChem, Micromass UK Ltd., Milestone Development Services, Millennium Pharmaceuticals Inc., Millennium Predictive Medicine, Molecular Mining Corp., Molecular Probes Inc., Molecular Simulations Inc. (Pharmacopeia), M-Scan, Myriad Genetics, Inc., Netgenics, Novartis Pharma AG, Novex (Invitrogen Corp.), Owl Separation Systems Inc., Oxford GlycoScience PLC, Oxford Molecular Group PLC, Parke Davis (Warner Lambert Ltd.), PE SCIEX, PerSeptive Biosystems (PE Bio), Pfizer, Pharmacia & Upjohn, Pharmagene Laboratories PLC, Phoretix International Ltd., Phylos Inc., Pierce Milwaukee Inc., ProCeryon Inc., Protagen AG, Protein Pathways Inc., Proteome Sciences PLC, Proteome Systems Ltd., Proteome Inc., ProteoMetrics LLC, Proteus PLC, R.Shadel Inc., Roche, Rockefeller PDTC, Rosetta Inpharmatics Inc., SAI Ltd., Savant/ EC Inc., Scanalytics Inc., SciMagix Inc., Sierra Analytics LLC, Sigma Chem, Sigma-Aldrich Co., Small Molecule Therapeutics Inc., Spotfire Inc., Stratagene Ltd., Structural Bioinformatics Inc., Structural Genomix Inc., Structure Function Genomics LLC, Synomics Ltd., Syrrx Inc., Target Discovery Inc., Textco Inc., Thermo BioAnalysis, ThermoQuest Corp. (Finnigan), Toplab GmbH, Varian Inc., Viaken Systems Inc., Vyrex Corp., Vysis, Xencor Inc., Xerion Pharmaceuticals GmbH, Zaxis Inc., Zyomyx Inc. |
